MIP3α expression. An interesting recombinant oncolytic NDV expressing the macrophage inflammatory protein MIP-3α (NDV-MIP3α) was engineered as an in vivo DC vaccine for amplifying anti-tumour immunity. This evidence concerns the gene CCL20 and neoplasm.